Why is RadNet, Inc. ?
- Poor long term growth as Operating profit has grown by an annual rate 53.28% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 6.12% signifying low profitability per unit of shareholders funds
- NET PROFIT(HY) At USD -9.92 MM has Grown at -854.14%
- RAW MATERIAL COST(Y) Grown by 9.06% (YoY)
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 1.77%, its profits have fallen by -46.6%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 6.27% over the previous quarter.
How much should you hold?
- Overall Portfolio exposure to RadNet, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is RadNet, Inc. for you?
High Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at USD 261.76 MM
Lowest at 108.11 %
Highest at 392.3
Highest at USD 1,550.47 MM
Highest at USD 498.23 MM
Highest at USD 71.45 MM
Highest at USD 28.66 MM
Highest at USD 19.09 MM
Highest at USD 0.19
At USD -9.92 MM has Grown at -854.14%
Grown by 9.06% (YoY
Here's what is working for RadNet, Inc.
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
Operating Cash Flows (USD MM)
Operating Profit to Interest
Debt-Equity Ratio
Net Sales (USD MM)
Operating Profit (USD MM)
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
EPS (USD)
Cash and Cash Equivalents
Here's what is not working for RadNet, Inc.
Raw Material Cost as a percentage of Sales






